Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Sun Pharma"
Count: 120
Selected: 0
NCT IDTitle
NCT03997786A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
NCT04991116Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04314544Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314531Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT03897075Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
NCT03897088Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasi
NCT03192137Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
NCT04487860Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
NCT02980692Efficacy and Safety Study of SUNPG1623
NCT01722331A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
NCT01808547Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
NCT01576952Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects
NCT01387464Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery
NCT01190878Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
NCT01408082Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
NCT00578955Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
NCT01478555A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
NCT00754949Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
NCT04357795Effect of Cequa™ in Subjects With Dry Eye Disease
NCT01543490Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
NCT03552276Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
NCT01729754A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT02980705Efficacy and Safety Study of SUNPG1622
NCT03718299A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
NCT02737332A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT031921502nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
NCT03992729Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
NCT02534896To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis
NCT03927443A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT02962284One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
NCT02254265Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02845674An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02688556Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT01936688A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
NCT04242953Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects
NCT03055143Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
NCT04942054A Study in Patients With Advanced Breast Cancer
NCT03655236PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
NCT03450629Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension
NCT03426267Evaluation of Efficacy and Safety of SDN-037
NCT00947661Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension
NCT00945958Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
NCT02629692Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies
NCT02597465A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
NCT04332549To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
NCT02970019Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
NCT03445338To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers
NCT01457352Efficacy and Safety of SPARC0921 in Subjects With Spasticity
NCT03316820Bioavailability Study of K0706 in Healthy Subjects
NCT03109249Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer